Pembrolizumab (Keytruda, Merck) may have ongoing benefits for people with advanced non-small-cell lung cancer expressing programmed death ligand 1 (PD-L1), extended follow-up of an open-label study shows.
Reuters Health Information
Pembrolizumab May Help Some With Advanced Non-Small-Cell Lung Cancer
